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Abstract
The recognition molecules of the lectin complement pathway are mannose-binding lectin and Ficolin -1, -2 and -3. Recently
deficiency of Ficolin-3 was found to be associated with life threatening infections. Thus, we aimed to develop a functional
method based on the ELISA platform for evaluating Ficolin-3 mediated complement activation that could be applicable for
research and clinical use. Bovine serum albumin (BSA) was acetylated (acBSA) and chosen as a solid phase ligand for Ficolins
in microtiter wells. Binding of Ficolins on acBSA was evaluated, as was functional complement activation assessed by C4, C3
and terminal complement complex (TCC) deposition. Serum Ficolin-3 bound to acBSA in a calcium dependent manner,
while only minimal binding of Ficolin-2 and no binding of Ficolin-1 were observed. No binding to normal BSA was seen for
any of the Ficolins. Serum C4, C3 and TCC deposition on acBSA were dependent only on Ficolin-3 in appropriate serum
dilutions. Deposition of down stream complement components correlated highly significantly with the serum concentration
of Ficolin-3 but not with Ficolin-2 in healthy donors. To make the assay robust for clinical use a chemical compound was
applied to the samples that inhibited interference from the classical pathway due to the presence of anti-BSA antibodies in
some sera. We describe a novel functional method for measuring complement activation mediated by Ficolin-3 in human
serum up to the formation of TCC. The assay provides the possibility to diagnose functional and genetic defects of Ficolin-3
and down stream components in the lectin complement pathway.
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Introduction
The complement system is an integral part of the innate
immune system that protects the host against invading pathogens.
Three distinct pathways constitute the complement system; the
classical pathway, the alternative pathway and the lectin pathway
[1]. The C1 complex initiates the classical pathway upon
recognition of immune complexes and dying host cells [2]. The
alternative pathway is spontaneously activated by C3 hydrolysis,
but it has also been reported that properdin, a stabilizer of the
alternative pathway convertase [3], is capable of initiating the
complement cascade [4]. The Ficolins and mannose-binding lectin
(MBL) in association with MBL/Ficolin-associated serine prote-
ases (MASPs) are the initiator molecules of the lectin pathway.
Three MASPs (21, 22 and 23) have been described so far and
the current notion is that MASP-2 is the main lectin pathway
activator. Upon recognition of pathogen-associated molecular
patterns or altered self by MBL and the Ficolins, the associated
proteases cleave C4 and C2, hereby activating the complement
cascade which ultimately leads to the formation of the TCC [5].
Deficiencies in the initiator molecules of the complement system
have resulted in a more profound understanding of the role of the
three pathways in the innate immune system. Individuals deficient
in the C1 complex, C4 and to a lesser degree C2 are likely to suffer
from severe bacterial infections and systemic lupus erythematosus
(SLE) [6]. Lack of factor D results in defect alternative pathway
activation and is associated with Neisserial meningitidis infections [7].
Mutations in the properdin gene resulting in complete absence of
properdin or expression of non-functional protein are also
associated with meningococcal disease [8], emphasizing the role
of the alternative pathway in the defence against meningococci.
Polymorphisms in both the promoter and coding region of the
MBL gene (MBL2) have been shown to influence the concentra-
tion and function of expressed MBL, resulting in deficiency [9].
Approximately 10–15% of the Caucasian population are func-
tional MBL deficient, making this the most common deficiency in
the complement system. In most cases, MBL deficient individuals
appear healthy; however, during certain settings MBL deficiency is
associated with increased risk for diseases and disease outcome [5].
The knowledge regarding the association between the Ficolins
and disease is scarce and comes primarily from association studies
of single nucleotide polymorphisms (SNPs) [10]. Several SNPs
have been described in the FCN1 gene encoding Ficolin-1 (also
referred to as M-Ficolin) [11]. Two of these SNPs, one located in
the promoter and one in exon 9 of the FCN1 gene have been
associated with susceptibility to rheumatoid arthritis [12]. SNPs in
the promoter and coding region of the FCN2 gene are associated
with concentration and function of the protein [13,14]. A few
association studies between FCN2 SNPs and Ficolin-2 (also
referred to as L-Ficolin) serum levels have been published [15–
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2 in disease. Several polymorphisms have been identified in the
promoter region of the gene (FCN3) encoding Ficolin-3 (also
referred to as H-Ficolin), but it appears that none of these are
associated with the varying levels found in serum [19]. However, a
frame shift mutation in exon 5 (FCN3 + 1637delC) of the FCN3
gene, leading to a premature termination of transcription was
shown to be associated with lower levels of Ficolin-3 in the
heterozygous state [19]. Ficolin-3 has been suggested to participate
in the clearance of dying host cells [20,21]. We have recently
described a patient with a history of severe recurrent infections
that was homozygous for the FCN3+1637delC mutation and had
no detectable Ficolin-3 in serum [22], suggesting that complete
lack of Ficolin-3 is a novel immunodeficiency associated with
disease.
The involvement of the complement system in various diseases
has stirred the development of several assays to evaluate
deficiencies in the three activation pathways. Screening for
complement deficiencies are now a days often conducted by
functional assays based on enzyme-linked immunosorbent assay
(ELISA) techniques for evaluating the classical, the alternative and
the MBL-mediated lectin pathway [23–25]. To our knowledge, no
assay that can assess complement activation mediated specifically
by the Ficolins in serum has been developed. Furthermore, the
high frequency of individuals deficient in MBL makes it difficult to
evaluate deficiencies in down stream lectin pathway components
such as MASP-2 using the currently existing functional assays.
Here we describe the development of an ELISA based assay for
the evaluation of Ficolin-3 mediated complement activation, that
will enable the detection of deficiencies and functional defects in
Ficolin-3 and its associated proteases. This assay will provide a
critical addition to the current functional assays used for evaluating
complement deficiencies.
Results
In order to assess the ability of acBSA to function as a ligand for
human Ficolins, we applied recombinant Ficolins in known
concentrations to microtiter wells coated with acBSA and assessed
the binding of the individual Ficolins using monoclonal antibodies.
When plates were incubated for 30 min at 37uC, we detected
binding of both rFicolin-2 and rFicolin-3, while no binding of
rFicolin-1 was seen (Figure 1A). Increasing the incubation time to
3 h at room temperature resulted in a greater binding of both
rFicolin-2 and rFicolin-3 and again, no binding of rFicolin-1 was
detected (Figure 1B). At both incubation times, rFicolin-3
appeared to bind better than rFicolin-2.
Next, we evaluated the binding of Ficolins and MBL from
human serum to acBSA. Immobilized acBSA was incubated with
a normal human serum pool (NHSP) and binding of the individual
Ficolins and MBL was detected by monoclonal antibodies. When
immobilized acBSA was incubated with serum for 30 min at 37uC,
only binding of Ficolin-3 was seen, while no Ficolin-1, Ficolin-2 or
MBL binding could be detected (Figure 2A). Incubating the plates
with serum for 3 h at room temperature resulted in a profound
increase in the binding of Ficolin-3 compared to the plate
incubated for 30 min at 37uC (Figure 2B). Furthermore, a low
binding of Ficolin-2 could be detected, while no Ficolin-1 or MBL
binding was seen (Figure 2B).
Ficolin-3 has been shown to contain a calcium-binding site in
the proximity of the ligand-binding site [26], suggesting that
calcium is required for Ficolin-3 binding to ligands. We examined
this by chelating calcium and magnesium from serum using EDTA
or calcium alone by EGTA with addition of Mg
2+. Binding of
serum Ficolin-3 to acBSA was completely abrogated in both
settings (Figure 2C), demonstrating that Ficolin-3 interacts with
acBSA in a calcium dependent manner.
In order to test whether the binding of Ficolins to acBSA
resulted in complement activation we coated microtiter wells with
either untreated BSA or acBSA and subsequently incubated with a
NHSP. Deposition of both C4 and C3 was observed in the wells
coated with acBSA, while only very small amounts of deposition
were seen in the BSA-coated wells incubated with the highest
serum concentrations (Figure 3A–B). Deposition of C4 and C3
on acBSA was almost completely abrogated with the addition
of EDTA or EGTA + Mg
2+ to the NHSP (Figure 3C–D),
demonstrating that complement activation on acBSA is calcium
dependent. Detection of TCC was obtained when the incubation
time of serum was increased to 45 min at 37uC. The result was
dose dependent deposition of TCC on acBSA where as no
activation was observed on BSA (Figure 3E).
Figure 1. Binding of recombinant Ficolins to acBSA. Microtiter plates were coated with acBSA and subsequently incubated with equal
concentrations of rFicolin-1 ( ), rFicolin-2 ( ), rFicolin-3 ( )a t( A) 30 min at 37uCo r( B) 3 h at RT. Binding was detected with monoclonal
antibodies directed against the individual proteins. Graphs show mean 6 SD (n=4).
doi:10.1371/journal.pone.0015443.g001
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that binds to acBSA under the experimental conditions used
(Figure 2). To further examine whether the complement activation
observed on acBSA was exclusively mediated by Ficolin-3 we
depleted serum of either Ficolin-2 or Ficolin-3 using specific
antibodies or a non-related isotype matched antibody as a control.
Depletion of Ficolin-2 and Ficolin-3 from serum was confirmed by
SDS-PAGE and Western blotting (Figure 4A). We then applied
the Ficolin-2 depleted, Ficolin-3 depleted and control serum to
immobilized acBSA and evaluated the C4 (Data S1), C3 (Data S2)
and TCC deposition (Figure 4B–C). Depletion of Ficolin-2
produced no obvious difference in complement deposition
compared to NHSP (Figure 4B). Furthermore, addition of 5 mg/
ml rFicolin-2 to the Ficolin-2 depleted serum did not show any
influence on the complement deposition. When adding Ficolin-3
depleted serum to the plates however, the complement deposition
was remarkably reduced (Figure 4C). Spiking the Ficolin-3
depleted serum with 25 mg/ml rFicolin-3 resulted in a reconsti-
tution of complement activation substantially, but not to the same
level as in non-depleted serum (Figure 4C). Serum from a Ficolin-3
deficient individual (2/2) previously described [22] was also
evaluated and showed only low complement deposition in the
highest serum concentration in level with the Ficolin-3 depleted
serum (Figure 4D). Reconstituting the deficient serum with
rFicolin-3 increased the deposition of complement components
almost to the level of the NHSP deposition curve (Figure 4D).
Individual serum samples could contain anti-bovine antibodies
[27] that potentially could mediate complement activation on
acBSA via the classical pathway and interfere with the
interpretation of the results. It has recently been shown that
sodium polyanethole sulfonate (SPS) within a concentration
window inhibits complement activation via the classical and the
alternative pathway but does not influence the lectin pathway [28].
To test whether this compound indeed inhibits classical comple-
ment pathway activation on albumin we coated microtiter plates
with human serum albumin (HSA) and rabbit-anti-HSA IgG to
create solid phase immune complexes. Serum pre-incubated with
0.5 mg/ml SPS before added to the wells and when we
subsequently evaluated C4, C3 and TCC deposition, SPS was
able to completely inhibit complement deposition of all the
components (Figure 5A), consistent with previous findings [28]. To
evaluate the effects of adding SPS to serum in the Ficolin-3 assay
Figure 2. Binding of serum Ficolins and MBL to acBSA. Microtiter plates were coated with acBSA and subsequently incubated with a NHSP for
either (A) 30 min at 37uCo r( B) 3 h at RT. Binding of Ficolin-1 ( ), Ficolin-2 ( ), Ficolin-3 ( ) or MBL ( ) was subsequently detected with
monoclonal antibodies directed against the individual proteins. (C) acBSA incubated with: NHSP ( ), NHSP with 10 mM EDTA ( ) or NHSP with
10 mM EGTA and 5 mM Mg
2+ ( ). Binding was detected with a monoclonal antibody against Ficolin-3. All graphs show mean 6 SD (n=3).
doi:10.1371/journal.pone.0015443.g002
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PLoS ONE | www.plosone.org 4 November 2010 | Volume 5 | Issue 11 | e15443based on acBSA we employed different sera: NHSP, NHSP
depleted of Ficolin-2 or Ficolin-3, respectively, NHSP depleted
and then reconstituted with rFicolin-2 or rFicolin-3, respectively,
and finally serum from the Ficolin-3 deficient individual (2/2)
with or without addition of rFicolin-3 and evaluated the C4 (Data
S1), C3 (Data S2) and the TCC deposition (Figure 5B–D).
Addition of SPS to normal serum and Ficolin-2 depleted serum
revealed no striking change in complement deposition (compare
Figure 4B with Figure 5B). Furthermore, reconstituting the
Ficolin-2 depleted serum with rFicolin-2 did not generate a
difference compared to serum with no rFicolin-2 application with
or without SPS. When evaluating Ficolin-3 depleted or Ficolin-3
deficient serum a residual complement deposition of TCC was
seen in high serum concentration (Figure 4C–D), however, when
adding SPS to these sera, the remaining activity was reduced to
base line levels - the only exception being a minimal activity from
the Ficolin-3 deficient serum (Figure 5C–D). Finally, the minimal
complement deposition observed on untreated BSA in low serum
dilutions was eliminated when adding SPS (Data S3).
Since the residual complement deposition in presence of SPS
was only seen in serum from the Ficolin-3 deficient individual and
not in the Ficolin-3 depleted serum, we wanted to examine this
further. Hence, we depleted the Ficolin-3 deficient serum of
Ficolin-2 and added rFicolin-2. The different sera were evaluated
for TCC deposition with and without SPS. The residual activity
was eradicated when the Ficolin-3 deficient serum was depleted of
Figure 3. Complement deposition of C4, C3 and TCC on acBSA. (A–B) Microtiter wells were coated with acBSA or BSA and subsequently
incubated with NHSP for 30 min at 37uC. (A) C4 and (B) C3 deposition on acBSA ( ) or BSA ( ) was detected using a polyclonal antibody. (C–D)
Microtiter wells were coated with acBSA and subsequently incubated with NHSP ( ), NHSP with 10 mM EDTA ( ) or NHSP with 10 mM EGTA and
5m MM g
2+ ( ) for 30 min at 37uC. (C)C 4o r( D) C3 deposition was detected as described above. (E) Finally, microtiter wells were coated with
acBSA ( ) or BSA ( ) and subsequently incubated with NHSP in serial dilution for 45 min at 37uC and TCC-deposition on acBSA was detected
using a monoclonal antibody. All graphs show mean 6 SD (n=4).
doi:10.1371/journal.pone.0015443.g003
Figure 4. TCC deposition on acBSA with depleted and deficient sera. Ficolin-2 or Ficolin-3 was depleted from serum using specific
monoclonal antibodies. (A) Depleted serum was applied to SDS-PAGE/Western blotting and probed for Ficolin-2 or Ficolin-3. Lane 1: Ficolin-3
depleted serum. Lane 2: Ficolin-2 depleted serum. Lane 3: Control depleted serum. (B–D) Microtiter plates were coated with acBSA and incubated for
45 min at 37uC with different sera before TCC deposition was detected with a monoclonal antibody. (B) Shows TCC deposition for: NHSP ( ),
Ficolin-2 depleted serum (-¤-), Ficolin-2 depleted serum with addition of 5 mg/ml rFicolin-2 ( ). (C) Shows TCC deposition for: NHSP ( ), Ficolin-
3 depleted serum (-&-) and Ficolin-3 depleted serum with addition of 25 mg/ml rFicolin-3 ( ). (D) Shows TCC deposition for: NHSP ( ), Ficolin-3
deficient serum 2/2 (-m-), Ficolin-3 deficient serum 2/2 with addition of 25 mg/ml rFicolin-3 ( ). All graphs show mean 6 SD of duplicate wells.
doi:10.1371/journal.pone.0015443.g004
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Figure 6A–B). Again, the addition of rFicolin-2 had no influence
on the complement activity.
Serum concentrations of Ficolin-2 and -3 in 116 blood donors
were determined. Ficolin-1 was not evaluated since a specific assay
for determining the serum concentration of Ficolin-1 was not
available to us. We then evaluated the C4 and C3 deposition on
acBSA from serum from the 116 individuals. No obvious
correlation of the Ficolin-2 serum concentration to either C4
(Figure 7A) or C3 (Figure 7C) deposition was observed. In
contrast, the deposition of both C4 (Figure 7B) and C3 (Figure 7D)
showed a significant positive correlation with the serum concen-
tration of Ficolin-3.
Finally, in order to establish whether this assay could detect
deficiencies in downstream components of the Ficolin-3 mediated
complement activation, we assessed the C4, C3 and TCC
deposition on acBSA using C2, C5 and properdin deficient sera,
respectively. All three sera mediated C4 deposition on acBSA
(Figure 8A). Both the C5 and properdin deficient sera mediated
C3 deposition at levels comparable to the serum pool that was
used as a control (Figure 8B). However, the C3 deposition was
almost completely abrogated when the C2 deficient serum was
applied (Figure 8B). Finally, when assessing the TCC, both the C2
and C5 deficient serum failed to mediate deposition on acBSA,
while the properdin deficient serum showed normal deposition of
the TCC (Figure 8C).
Discussion
Deficiencies in the complement system are often associated with
recurrent infections and autoimmune diseases [6]. We have
recently described a patient suffering from recurrent infections and
obstructive lung disease that was homozygous for the FCN3 +
1637delC mutation, resulting in complete deficiency of Ficolin-3
Figure 5. Inhibition of the classical pathway of complement activation with SPS. (A) Classical pathway activation was obtained by coating
microtiter wells with HSA and subsequently incubated with a rabbit-anti-HSA antibody. A NHSP was pre-incubated with or without SPS for 5 min on
ice and then applied to the microtiter wells for 30 min (45 min for TCC-detection) at 37uC. Complement activation was detected with biotinylated
antibodies. In the absence of SPS: C4 ( ), C3 ( ) or TCC ( ); and in the presence of SPS: C4 ( ), C3 (-N-) or TCC (-%-). (B–D) Different sera pre-
incubated on ice with SPS and then incubated for 45 min at 37uC in microtiter plates coated with acBSA before TCC deposition was detected with a
monoclonal antibody. (B) Shows TCC deposition in the presence of SPS for: NHSP ( ), Ficolin-2 depleted serum (-¤ -), Ficolin-2 depleted serum
with addition of 5 mg/ml rFicolin-2 ( ). (C) Shows TCC deposition in the presence of SPS for: NHSP ( ), Ficolin-3 depleted serum (-&-) and
Ficolin-3 depleted serum with addition of 25 mg/ml rFicolin-3 ( ). (D) Shows TCC deposition in the presence of SPS for: NHSP (-&-), Ficolin-3
deficient serum 2/2 (-m-), Ficolin-3 deficient serum 2/2 with addition of 25 mg/ml rFicolin-3 ( ). All graphs show mean 6 SD of duplicate wells.
doi:10.1371/journal.pone.0015443.g005
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approximately 0.01 in the Danish population [19]. Thus, one
would expect that 1 out of 10.000 Caucasian individuals would be
homozygous for the FCN3 + 1637delC mutation. The likely
association between Ficolin-3 deficiency and disease was the
primary motivation for this report, since we sought to develop an
assay that could assess complement activation mediated specifi-
cally by Ficolin-3. Such assay could aid the identification of
individuals with functional and genetic deficiencies of Ficolin-3
and perhaps also serve as a useful diagnostic tool in collaboration
with the existing assays for evaluating complement function.
Acetylated compounds have previously been shown to function
as ligands for the Ficolins [29–31]. However, the observation that
serum deficient of Ficolin-3 did not mediate C4 deposition on
acBSA [22] prompted us to investigate whether this ligand would
be suitable for assessing Ficolin-3 mediated complement activa-
tion. The observed binding of rFicolin-2 was in accordance with
previous studies [30], however it was of interest that rFicolin-3
appeared to bind even better than rFicolin-2. The rFicolin-1 used
for this study displayed the characteristic oligomeric pattern when
applied to SDS-PAGE/Western blotting under non-reducing
conditions and was fully functional in another binding assay
[32]. Thus, the specific assay conditions applied in this assay are
the likely explanation for the lack of binding of rFicolin-1.
Interestingly, when evaluating the binding of serum Ficolins, we
only observed binding of Ficolin-3 to acBSA when incubated with
serum for 30 min at 37uC. One plausible explanation for this
could be the difference in serum concentration of Ficolin-2 and
Ficolin-3. Ficolin-2 circulates at a mean concentration of 5.4 mg/
ml [14], while Ficolin-3 circulates at an approximately five-fold
higher mean concentration [19]. However, when evaluating
binding of the recombinant Ficolins added in equal concentra-
tions, rFicolin-3 still appeared to have a better binding capacity to
acBSA at the applied assay conditions compared to rFicolin-2.
Based on the initial binding results of serum Ficolins to acBSA,
we decided to proceed with the evaluation of C4 and C3
deposition on acBSA using the 30-minute, 37uC serum incubation
step, since this appeared to provide the properties for Ficolin-3
binding to acBSA without interference from Ficolin-2. The
complement deposition on acBSA yielded a serum dose dependent
curve and only a small amount of C3 deposition on untreated BSA
was evident in the highest serum concentration. This could be a
result of passive absorption from serum, or the marginal
generation of active C3-convertases. These results demonstrate
that the complement deposition in intermediate serum dilutions is
specific for acetylated BSA and not untreated BSA.
The binding site of Ficolin-3 to ligands is through the
fibrinogen-like domain and the crystal structure of Ficolin-3 has
shown that a calcium-binding site is located in the vicinity of the
binding site, suggesting that calcium might be required for Ficolin-
3 binding to its ligand [26]. In agreement with this, we observed
that the binding of serum Ficolin-3 to acBSA was completely
absent in the presence of EDTA and EGTA/Mg
2+ as were the
deposition of complement components C4 and C3.
Evaluating depleted sera showed, that Ficolin-2 does not
contribute substantially to complement deposition in this assay.
Adding rFicolin-3 to Ficolin-3 depleted serum, complement
activation on acBSA was reconstituted, though not to the level
of full serum. A reasonable explanation for this is that when serum
is depleted of Ficolin-3, a certain amount of MASPs are also
depleted since Ficolin-3 circulates in complex with the MASPs.
Hence, addition of rFicolin to the depleted serum reconstitutes
some complement activation; however, the MASPs will still
remain as a limiting factor for complement activation. The
Ficolin-3 deficient serum described by Munthe-Fog et al. [22]
showed the same absence of complement deposition on acBSA as
the Ficolin-3 depleted serum. Reconstitution of complement
activation with rFicolin-3 allowed full restoration of complement
activity. This observation substantiates the explanation that
MASPs are removed from serum along with Ficolin-3 in the
Ficolin-3 depleted serum. The level of MASPs in the Ficolin-3
deficient serum is unaffected and may thus not be a limiting factor
of complement activation in this serum as in the Ficolin-3 depleted
serum.
We did not deplete serum of Ficolin-1, since we did not have
any specific antibodies against this protein. However, considering
the low concentration of Ficolin-1 in serum [33,34] and the
observation that rFicolin-1 did not interact with acBSA, it appears
likely that Ficolin-1 does not mediate complement activation at the
applied assay conditions. Moreover, it has been shown that the
complement activating potential of Ficolin-1 is very low compared
with that for Ficolin-2 and Ficolin-3 [35].
Figure 6. TCC deposition on acBSA with Ficolin-3 deficient serum depleted of Ficolin-2 without and with SPS. Serum pre-incubated on
ice (A) without SPS or (B) with SPS and then incubated for 45 min at 37uC on microtiter plates coated with acBSA. The sera analysed was: Ficolin-3
deficient serum 2/2 ( ), Ficolin-3 deficient serum 2/2 depleted of Ficolin-2 ( ), Ficolin-3 deficient serum 2/2 depleted of Ficolin-2 with
addition of 5 mg/ml rFicolin-2 ( ). TCC deposition was detected with a monoclonal antibody. Graphs show mean 6 SD of duplicate wells.
doi:10.1371/journal.pone.0015443.g006
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suggesting that MBL does not influence the complement activation
on acBSA. This is in agreement with previous results, which
demonstrated that MBL defect serum mediated C4 deposition on
acBSA at levels comparable to a NHSP [22]. Furthermore, we
have previously shown that C1q deficient serum is capable of
depositing C4 on acBSA at levels comparable to normal human
serum, suggesting that the complement activation occurs inde-
pendently of the classical pathway [22]. However, interference
from the classical pathway on acBSA could potentially occur in
serum containing anti-bovine antibodies [27].
A recent study has shown that sodium polyanethole sulfonate
(SPS) within a certain concentration window inhibits complement
activation via both the classical and the alternative pathway and
leaves the lectin pathway unaffected [28]. Here, we demonstrate
that SPS can inhibit classical pathway activation without
significantly influencing complement activation from normal
human serum on acBSA. On the other hand, deposition of
complement on untreated BSA was abolished in the presence of
SPS. When evaluating complement deposition on acBSA with
Ficolin-3 deficient or depleted serum, residual complement
activation in high serum concentrations seen without SPS was
abolished in the presence of SPS. However, even with SPS the
Ficolin-3 deficient serum still showed a minimal complement
activating activity in the highest serum concentration. We
speculated whether this could be due to a minor contribution of
complement activation from Ficolin-2 according to the binding
experiments. Hence, in an individual with Ficolin-3 deficiency,
Ficolin-2 would probably under optimized conditions be able to
exhibit some binding to acBSA with the lack of competition from
Figure 7. Correlation of C4 and C3 deposition on acBSA to Ficolin-2 and -3 serum concentrations. Microtiter wells were coated with
acBSA and subsequently incubated with individual serum samples in triplicates for 30 min at 37uC. The relative deposition of C4 and C3 on acBSA
from serum from 116 individuals was determined using a NHSP as standard (100%). Ficolin-2 and Ficolin-3 concentrations in serum were determined
as described in materials and methods. The graphs show the deposition of C4 as a function of (A) Ficolin-2 or (B) Ficolin-3 serum concentrations and
the deposition of C3 as a function of the (C) Ficolin-2 and (D) Ficolin-3 serum concentrations. P-values and Spearman rank (r) were calculated using
the GraphPad Prism software. (n=116).
doi:10.1371/journal.pone.0015443.g007
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MASPs, and the pattern recognition molecules of the lectin
pathway will be skewed towards Ficolin-2 in the Ficolin-3 deficient
serum and therefore could increase the complement activation
potential of Ficolin-2. Contrarily, in the case of the Ficolin-3
depleted serum, a certain amount of MASPs will be removed from
serum in complex with Ficolin-3 in the action of depletion.
Consequently, the remaining Ficolin-2 would lack endogenous
MASPs for complement activation.
To further investigate the possible contribution of Ficolin-2 in
this assay, we depleted Ficolin-3 deficient serum of Ficolin-2 and
evaluated it in the presence of SPS. We ascribe the residual activity
from this serum only seen in the highest serum concentrations to
Ficolin-2, which could also fit with the results of the binding
experiments. Nevertheless, in diluted serum this potential problem
seems to disappear.
The positive correlation between Ficolin-3 concentration and
complement activation in 116 serum samples, further substantiates
our observations that complement activation on immobilized
acBSA under the specific assay conditions employed is primarily
mediated by Ficolin-3 and not Ficolin-2, which displayed no
correlation. In the correlation plot of Ficolin-3 to C4 and C3
deposition several samples are observed with a rather high serum
concentration of Ficolin-3 but yet a relatively low complement
activation value. This is likely due to individuals with lowered
levels of components further down the complement cascade such
as MASP-2, C4 or C2, which will skew the level of complement
activation. It should be noted that the inhibitor SPS was not added
to the assay buffer when measuring the donor samples, which to
some extend could blur the Ficolin-3 results. However, it would be
obvious to utilize SPS in the final assay.
In order to address whether the Ficolin-3 mediated complement
activation on acBSA would detect deficiencies in downstream
complement components, we used sera deficient in C2, C5 and
properdin, respectively [36,37]. C4 deposition was observed at
comparable levels to the control NHSP for the C2 deficient serum,
while the C3 and the TCC deposition were completely absent.
This demonstrates that the formation of a C4bC2a convertase is
required for complement activation on acBSA, suggesting that
there is no involvement of the alternative pathway. In agreement
with this, the properdin deficient serum was fully capable of
activating complement on acBSA. The different levels of C4 and
Figure 8. Complement activation on acBSA using C2, C5 or properdin deficient serum. Microtiter plates were coated with acBSA and
subsequently incubated with NHSP ( ), C2 deficient serum ( ), C5 deficient serum ( ) or properdin deficient serum ( ) in serial dilutions for
30 min at 37uC. (A) C4 deposition and (B) C3 deposition on acBSA measured using polyclonal antibodies. (C) TCC deposition on acBSA measured
using a monoclonal antibody. All graphs show mean 6 SD (n=3).
doi:10.1371/journal.pone.0015443.g008
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likely a result of inter-individual differences in the Ficolin-3
concentrations or other complement components. Taken together,
these results demonstrate that the Ficolin-3 mediated complement
activation assay is suitable to detect deficiencies in downstream
components of the complement cascade.
Homozygosity for an amino acid substitution in MASP-2
(D120G) is causing very low levels of MASP-2 and deficiency in
lectin pathway-mediated complement activation [38]. MASP-2
deficiency due to D120G homozygosity has been reported in few
patients suffering from multiple infections and/or autoimmune
symptoms [38–40], but also in apparently unaffected individuals
[41], suggesting that MASP-2 deficiency is not necessarily
associated with disease, but might function as a disease modifier.
Although not formally tested in this study, it is likely that Ficolin-3
mediated complement activation on acBSA will also detect MASP-
2 deficiency. The high frequency of MBL deficiency and
functional defects [5,9] makes MBL mediated complement
function assays unsuitable for elucidation of deficiencies down-
stream of MBL itself. The described Ficolin-3 deficiency would
occur in approximately 1 out of 10.000 Caucasian individuals
[19,22], making the Ficolin-3 mediated complement activation
much more suitable for detection of deficiencies of components
downstream of the lectin pathway than an MBL dependent assay.
In this assay we have strived towards as physiological conditions
as possible concerning incubation temperature and time, pH and
ion concentration of the buffer. Since all three Ficolins have been
shown to bind to acetylated compounds the importance of keeping
the assay conditions under strict surveillance should be stressed.
When measuring the C4 and C3 deposition mediated specifically
by Ficolin-3, we suggest that the serum is diluted at least 1:100 and
incubated for 30 minutes at 37uC. Using an intermediate serum
dilution should circumvent interference from the alternative as
well as the classical pathway as well as from Ficolin-2; however,
since SPS appears to be an excellent inhibitor of classical pathway
and also has been reported to inhibit the alternative pathway, we
recommend to add this reagent in the serum incubation step
according to Palarasah et al. [28]. An alternative could be to block
the classical pathway with an anti-C1q antibody that has been
shown to work well in MBL dependent complement activation
assays [24]. In the case of detection of TCC, the serum
concentration should be higher, in order to obtain a proper
signal. Furthermore, the incubation time should be increased to 45
minutes at 37uC. Again, the use of SPS will circumvent any
interference from the other pathways.
Taken together, our results demonstrate that complement
activation on immobilized acBSA under the described assay
conditions is specifically mediated by Ficolin-3. To our knowledge,
this is the first assay that is capable of evaluating complement
activation mediated by Ficolin-3 and down stream components
and thus will provide a critical supplement to the already existing
assays for evaluating complement function and genetic defects.
Materials and Methods
Materials
Maxisorp microtiter plates were purchased from NUNC
(Roskilde, Denmark). PBS-buffer (10 mM Na2HPO4, 1.47 mM
KH2PO4, 137 mM NaCl, 2.7 mM KCl, pH=7.4), Barbital-buffer
(4 mM C8H11N2NaO3, 145 mM NaCl, 2.6 mM CaCl2, 2.1 mM
MgCl2, pH=7.4) and 1 M sulphuric acid were all acquired from
the hospital pharmacy (Region H Apoteket, Rigshospitalet,
Copenhagen, Denmark). Tween-20 was purchased from Merck
(Hohenbrunn, Germany). Bovine serum albumin (BSA), human
serum albumin (HSA), sodium acetate solution, acetic anhydride
and sodium polyanethole sulfonate (SPS) (Cat.no. P2008-5G) were
all purchased from Sigma-Aldrich (Copenhagen, Denmark).
Rabbit anti-C4c polyclonal antibody, Horseradish-peroxidase
(HRP) conjugated rabbit anti-mouse IgG and OPD substrate
tablets were purchased from DAKO (Glostrup, Denmark). Rabbit
anti-C3c polyclonal antibody was purchased from Dade Behring
(Marburg, Germany). Mouse anti-C5b-C9 terminal complement
complex (TCC) monoclonal antibody was purchased from
BioportoDiagnostics(Gentofte, Denmark).Horseradish peroxidase
(HRP) conjugated rabbit anti-mouse IgG, donkey anti-rabbit IgG
and streptavidin were purchased along with nitrocellulose mem-
branes from GE Healthcare (Buckinghamshire, United Kingdom).
Magnetic Dynabeads conjugated with anti-mouse IgG antibodies,
NuPAGE 10% Bis-Tris gels, 3–8% Tris-acetate gels, MOPS-
buffer, Tris-acetate buffer, LDS loading buffer and reducing agent
were purchased from Invitrogen (Taastrup, Denmark).
Recombinant Ficolins (rFicolin)
Recombinant Ficolin-1, -2 and –3 were generated as previously
described for rFicolin-2 [42]. Briefly, the Ficolin genes were
amplified and tagged with a hexa-histidine sequence in the C-
terminal end. The constructs were cloned into expression vectors
and transfected into Chinese hamster ovarian cells. His-tagged
rFicolin was purified from the supernatant of the cells on a Ni-
NTA column (Qiagen, West Sussex, United Kingdom).
Monoclonal antibodies against Ficolins
Monoclonal antibodies were generated against Ficolin-1
(FCN106), Ficolin-2 (FCN216 and FCN219) and Ficolin-3
(FCN334) and have all been characterized previously [14,19,33].
It should be noted that FCN106 shows a slight cross-reactivity with
Ficolin-2. A monoclonal antibody against MBL (Hyb-131-10) was
purchased from BioPorto Diagnostics (Gentofte, Denmark).
Biotinylated polyclonal antibodies against Ficolin-2 and Ficolin-3
were purchased from R&D systems (Abingdon, UK). Biotinylation
of antibodies was conducted by incubating 0.5 mg/ml antibody
with 100 mg Biotin-N-hydroxysuccinimide ester (Sigma-Aldrich,
Copenhagen, Denmark) for 3 h end-over-end at room tempera-
ture. Subsequently the antibodies were dialysed against PBS.
Acetylation of albumin
A 10% dilution (w/v) of BSA in H2O was prepared. A total of
500 ml of the 10% albumin solution was mixed with 500 mlo f
saturated sodium acetate solution (0.74 g/ml). The solution was
placed on ice for 1 h and during this period acetic anhydride was
added to the solution in 12-minute intervals to a final volume of
50 ml. The acetylated albumin was dialysed against PBS-buffer
and the protein concentration was determined by measuring the
absorbance at 280 nm.
Serum samples
Approval for this study was obtained from The Committees on
Biomedical Research Ethics of the Capital Region of Denmark.
Blood from 116 blood donors was collected with written informed
consent in serum glass. Serum was separated from the coagulate
by centrifugation (16006g for 10 min) and subsequently stored at
280uC. A serum pool (NHSP) was established based on thirty
randomly selected donors out of the 116 donors above. Ficolin-3
deficient serum was obtained from a patient previously described
[22]. C2 and C5 deficient serum was obtained from individuals
characterized as previously described [36]. Properdin deficient
serum was obtained from an individual previously described [37].
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Concentrations of Ficolin-2 and Ficolin-3 in the established serum
pool or individual donors were determined using previously
established assays [14,19]. Briefly, a monoclonal antibody directed
against Ficolin-2 (FCN216) or Ficolin-3 (FCN334) was coated onto
microtiter plates in PBS overnight at 4uC. Diluted serum samples
was applied to the plates and incubated for 3 h. A standard dilution
seriesof pooled human serum with known concentration ofFicolin-2
and Ficolin-3 were added to each assay. Plates were washed and
subsequently incubated with a biotinylated Ficolin-2 antibody
(FCN219-Biotin) or Ficolin-3 antibody (FCN334-Biotin) overnight
at 4uC. HRP-conjugated streptavidin was added to the wells and
incubated for 1 h. After washing, OPD substrate solution containing
H2O2 was added and plates were developed for 10–15 min.
Addition of 50 ml/well sulphuric acid terminated the enzymatic
reaction and the optical density was measured at 490 nm.
Depletion of Ficolin-2 and Ficolin-3 from serum
Serum from the NHSP was diluted 1:1 in buffer and incubated
for 20 min at 4uC with a monoclonal antibody against Ficolin-2
(FCN219), Ficolin-3 (FCN334) or an isotype matched IgG with no
human specificity as a control. Following incubation, magnetic
dynabeads conjugated with anti-mouse IgG antibodies (Dyna-
beads Pan Mouse IgG), was added to the serum samples and
incubated end-over-end for 30 min. The tubes were then placed
on a magnetic rag and the serum supernatant was removed.
Incubation with antibodies and beads was repeated once to ensure
full depletion. Depletion was confirmed by SDS-PAGE/western
blotting using the NuPAGE system according to manufactures
protocols (Invitrogen, Taastrup, Denmark).
Ficolin binding to acetylated BSA (acBSA)
Microtiter plates were coated with 5 mg/ml acBSA in 100 ml/
well volumes in PBS-buffer overnight at 4uC. Plates blocked for
1 h with barbital-buffer containing 0.05% tween (barbital-T) and
were subsequently washed thrice in barbital-T. Serum diluted in
barbital-T or rFicolins was added to the wells and incubated for
30 min at 37uC or 3 h at room temperature. In order to evaluate
whether the binding was dependent on magnesium and calcium
10 mM EDTA or 10 mM EGTA with 5 mM Mg
2+ was added to
the serum. Following incubation, plates were incubated with 1 mg/
ml of biotinylated monoclonal antibody against Ficolin-1, Ficolin-
2, Ficolin-3 or MBL for 2 h at room temperature, shaking. After
washing, HRP-conjugated streptavidin was added for 1 h, room
temperature. Plates were washed and developed for 10–15 min
with OPD substrate containing H2O2. Addition of 50 ml/well
sulphuric acid terminated the enzymatic reaction. The optical
density was measured at 490 nm.
Ficolin-3 complement activation assay
Microtiter plates were coated with 5 mg/ml acBSA in PBS-
buffer overnight at 4uC. Plates were blocked for 1 h with barbital-
T and subsequently washed thrice in barbital-T. Serum diluted in
barbital-T was added to the wells and incubated for 30 min at
37uC (45 min at 37uC for the detection of TCC). In order to
evaluate whether the binding was dependent on calcium 10 mM
EDTA or 10 mM EGTA with 5 mM Mg
2+ was added to the
serum. Plates were washed in barbital-T and subsequently
incubated with anti-C4c (0.13 mg/ml), anti-C4c-biotin (2 mg/ml),
anti-C3c (0.32 mg/ml) or anti-C5b-C9 (TCC) (1 mg/ml) for 2 h,
shaking at room temperature. Plates were washed in barbital-T
and incubated with HRP-conjugated streptavidin, anti-rabbit or
anti-mouse IgG antibodies (all diluted 1:2000 in barbital-T) for 1 h
at room temperature, shaking. Plates were washed and developed
as described above.
Classical pathway activation assay
Microtiter plates were coated with 5 mg/ml human serum
albumin (HSA) in PBS overnight at 4uC. The plates were washed
in barbital-T and incubated with 2 mg/ml polyclonal rabbit anti-
HSA IgG for 2 h at room temperature as described by Palarasah
et al. [28]. Plates were washed as before and incubated with
dilutions of serum in barbital-T for 30 min at 37uC. Following
incubation, plates were washed and incubated with 2 mg/ml
biotinylated anti-C4c or anti-C3c polyclonal antibody, or anti-
C5b-9 monoclonal antibody for 2 h at room temperature and
subsequently HRP-conjugated streptavidin or HRP-conjugated
anti-mouse IgG, respectively, for 1 h at room temperature. Plates
were washed and developed as described above. Inhibition of the
classical pathway was conducted as previously described by
Palarasah et al. [28]. In brief, full serum was pre-incubated for
5 min on ice with SPS dissolved in TBS to a final concentration of
0.5 mg/ml. Subsequently, serum with SPS was diluted in barbital-
T and added to the microtiter plates in serial dilutions.
Statistical analysis
All statistical analysis were conducted using GraphPad Prism 4
software (La Jolla, CA, USA).
Supporting Information
Data S1 C4 deposition on acBSA with depleted and
deficient sera. Ficolin-2 or Ficolin-3 was depleted from serum
using specific monoclonal antibodies. Depleted and deficient sera
pre-incubated on ice with or without SPS and were then added to
microtiter plates coated with acBSA and incubated for 30 min at
37uC. C4 deposition was detected with a polyclonal antibody. (A)
Ficolin-2 depleted serum analysed without SPS or (B) with SPS:
NHSP ( ), Ficolin-2 depleted serum (-¤-), Ficolin-2 depleted
serum with addition of 5 mg/ml rFicolin-2 ( ). (C) Ficolin-3
depleted serum analysed without SPS or (D) with SPS: NHSP
(-&-), Ficolin-3 depleted serum (-&-) and Ficolin-3 depleted
serum with addition of 25 mg/ml rFicolin-3 ( ). (E) Ficolin-3
depleted serum analysed without SPS or (F) with SPS: NHSP
( ), Ficolin-3 deficient serum 2/2 (-m-), Ficolin-3 deficient
serum 2/2 with addition of 25 mg/ml rFicolin-3 ( ). All graphs
show mean 6 SD of duplicate wells. (TIF)
Data S2 C3 deposition on acBSA with depleted and
deficient sera. Ficolin-2 or Ficolin-3 was depleted from serum
using specific monoclonal antibodies. Depleted and deficient sera
pre-incubated on ice with or without SPS and were then added to
microtiter plates coated with acBSA and incubated for 30 min at
37uC. C3 deposition was detected with a polyclonal antibody. (A)
Ficolin-2 depleted serum analysed without SPS or (B) with SPS:
NHSP ( ), Ficolin-2 depleted serum (-¤-), Ficolin-2 depleted
serum with addition of 5 mg/ml rFicolin-2 ( ). (C) Ficolin-3
depleted serum analysed without SPS or (D) with SPS: NHSP
( ), Ficolin-3 depleted serum (-&-) and Ficolin-3 depleted serum
with addition of 25 mg/ml rFicolin-3 ( ). (E) Ficolin-3 depleted
serum analysed without SPS or (F) with SPS: NHSP
( ), Ficolin-3 deficient serum 2/2 (-m-), Ficolin-3 deficient
serum 2/2 with addition of 25 mg/ml rFicolin-3 ( ). All graphs
show mean 6 SD of duplicate wells. (TIF)
Data S3 C4 and C3 deposition on BSA with or without
SPS. A NHSP pre-incubated on ice without SPS ( ) or with
SPS ( ) and then incubated for 30 min at 37uC on microtiter
plates coated with BSA. (A) C4 and (B) C3 deposition on untreated
Ficolin-3 Mediated Complement Activation
PLoS ONE | www.plosone.org 11 November 2010 | Volume 5 | Issue 11 | e15443BSA was detected with polyclonal antibodies, respectively and (C)
TCC deposition with a monoclonal antibody. Graphs show mean
6 SD of duplicate wells. (TIF)
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